The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TPG Asia VII SF Pte Ltd
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Smallcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TPG Asia VII SF Pte. Ltd, a Singapore-based private equity investor (not a promoter), sold 2,08,41,439 equity shares of Sai Life Sciences Ltd (face value ₹1 each) through an on-market transaction on June 20, 2025. This represents 10.00% of the company's total issued and paid-up equity share capital. After the sale, TPG's holding in Sai Life Sciences has come down from 5,15,48,272 shares (24.73%) to 3,07,06,833 shares (14.73%). The disclosure was filed on June 23, 2025 under SEBI's takeover regulations. No encumbrance or pledge-related activity is involved in this transaction.
This is a significant FII sell-down by one of the company's largest institutional shareholders, which may put short-term pressure on the stock. However, TPG continues to hold a substantial 14.73% stake, indicating it is a partial exit rather than a complete departure.